undamentalytics Newsletter
Sign in

Benitec Biopharma Inc. income statement

In fiscal 2024, Benitec Biopharma Inc. reported revenue of $0, down 100.0% on the year before and net income of −$21.8m, or −$1.22 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 2024LTMMar 2025
Revenue12000000
Research and development53711131619
General and administrative56776719
Operating income3−8−14−18−19−22−37
Net income3−8−14−18−20−22−34
Diluted EPS$0.05−$0.01−$0.21−$0.29−$0.32−$1.22—
Diluted shares (average)53m64m67m64m61m18m—
EBITDA3−8−13−18−19−22−37

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Benitec Biopharma Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Benitec Biopharma Inc.